Chimerix Inc. (CMRX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
On Tuesday, Jazz Pharmaceuticals plc JAZZ agreed to acquire Chimerix Inc CMRX for $8.55 per share in cash, representing a total consideration of approximately $935 million.
Jazz Pharmaceuticals to buy Chimerix for $935 million
Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies said on Wednesday.
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients
The company holds potential to have first approval of dordaviprone for the treatment of recurrent H3 K27M mutant high-grade glioma patients; PDUFA with Priority Review date of August 18th of 2025. The global brain tumor therapeutics market is expected to grow to $5.28 billion by 2030; the Company notes that it could obtain >$1 billion in revenues in the United States alone. Phase 3 ACTION study using dordaviprone for the treatment of front-line H3 K27M mutant high-grade glioma patients to have OS interim data readout in Q3 of 2025.
Here's Why Momentum in Chimerix (CMRX) Should Keep going
Chimerix (CMRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know
Chimerix stock surges 324% in three months following NDA submission for high-grade glioma drug, dordaviprone, for accelerated approval in the United States.
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diffuse midline glioma bolster confidence in FDA approval, despite potential timeline uncertainties. Financially, CMRX has a cash runway of 6–7 quarters, sufficient to reach an FDA decision, but risks of dilution remain.
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX ) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET Company Participants Will O'Connor - Investor Relations Mike Andriole - President and Chief Executive Officer Josh Allen - Chief Scientific Officer Michelle LaSpaluto - Chief Financial Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Operator Good morning, ladies and gentlemen and welcome to the Chimerix Third Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today's call, Will O'Connor from Stern Investor Relations.
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
Chimerix (CMRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.
Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago.
